Description
Tesamorelin supplied as a research reagent for in-vitro laboratory use. Every lot is assayed by reverse-phase HPLC to ≥98% purity, with identity confirmed by mass spectrometry and residual water content checked by Karl Fischer titration. Purity is verified across multiple independent laboratories, and material is sourced across multiple manufacturers so the highest-purity batch can be selected for release.
Specification
- CAS number: 218949-48-5
- Physical form: Lyophilised powder
- Purity: ≥98% by RP-HPLC
- Storage: 2°C – 8°C, protect from light
Research findings
- A stabilised analogue of growth hormone-releasing hormone; binds GHRH receptors on the anterior pituitary, stimulating endogenous growth hormone secretion, which in turn raises IGF-1 [1]
- Studied in a Phase 3 randomised controlled trial in 412 adults with HIV-associated lipodystrophy over 26 weeks, with visceral adipose tissue measured by CT [1]
- Examined in a pooled analysis of two Phase 3 trials covering 806 participants [2]
- Investigated for effects on liver fat in adults with HIV-associated fat accumulation [3]
- The evidence base is confined to HIV-associated lipodystrophy; use outside that population is outside the approved indication and not supported by these trials
- Prohibited in sport under the World Anti-Doping Agency List
Regulatory status
RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION. Supplied strictly for in-vitro laboratory research by qualified professionals. Not a medicine, supplement, cosmetic or food. Must not be administered to humans or animals.
Vial and carton labels show 99% purity — the specification we aim for on every batch. Our guaranteed minimum is ≥98% by RP-HPLC, and the measured result for each batch appears on its certificate of analysis.
Reviews
There are no reviews yet.